Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2026 |
|---|---|
| Revenue | — |
| R&D expense | $6.1M |
| Operating income | −$8.8M |
| Net income | −$115.3M |
| Cash & equivalents | $4.8M |
| Total debt | $373.7M |
| Operating cash flow | −$5.8M |
| Free cash flow | −$5.8M |
Company profile
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.